	Johns Hopkins Health Plans Pharmacy Public Medical Management Drug Policies	<i>Policy Number</i>	MMDP104
		<i>Effective Date</i>	07/17/2024
		<i>Approval Date</i>	07/17/2024
	<i>Subject</i> Blincyto	<i>Supersedes Date</i>	N/A
		<i>Page</i>	1 of 2

This document applies to the following Participating Organizations:

US Family Health Plan

Keywords: Blincyto

Table of Contents	Page Number
I. POLICY	1
II. POLICY CRITERIA	1
III. AUTHORIZATION PERIOD/LIMITATIONS	1
IV. EXCLUSIONS	1
V. RECOMMENDED DOSE	1
VI. CODES	1
VII. REFERENCES	2
VIII. APPROVALS	2

I. POLICY

- A. Blincyto (blinatumomab) will require prior authorization for medical benefit coverage to ensure appropriate use. The process for initiating a prior authorization request can be found in policy PHARM 20.

II. POLICY CRITERIA

- A. Blincyto may be approved for patients who meet the following:
1. Documentation has been submitted showing the following:
 - a. Diagnosis of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) confirmed by laboratory testing
 - b. Blincyto will be used in one of the following scenarios:
 - I. As consolidation or maintenance therapy
 - II. For relapsed or refractory disease

III. AUTHORIZATION PERIOD/LIMITATIONS

- A. Initial approval will be limited to 9 months of therapy
- B. Continuation of therapy may be approved in 12-month intervals with documentation showing the patient has not experienced unacceptable toxicity or disease progression while on the current regimen

IV. EXCLUSIONS


- A. Blincyto will not be covered for the following:
1. Any indications or uses that are not FDA-approved, or guideline-supported

V. RECOMMENDED DOSE

Please refer to the FDA-approved prescribing information, or clinical guidelines, for indication-specific dosing details.

VI. CODES

CPT Copyright 2013 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

 JOHNS HOPKINS HEALTH PLANS	Johns Hopkins Health Plans Pharmacy Public Medical Management Drug Policies	<i>Policy Number</i>	MMDP104
		<i>Effective Date</i>	07/17/2024
		<i>Approval Date</i>	07/17/2024
	<i>Subject</i> Blincyto	<i>Supersedes Date</i>	N/A
		<i>Page</i>	2 of 2

Note: The following CPT/HCPCS codes are included below for informational purposes. Inclusion or exclusion of a CPT/HCPCS code(s) below does not signify or imply member coverage or provider reimbursement. The member's specific benefit plan determines coverage.

Medication	HCPCS/CPT Code
Injection, blinatumomab, 1 microgram	J9039

VII. REFERENCES

1. Blincyto [prescribing information]. Thousand Oaks, CA: Amgen Inc.; June 2023.
2. The NCCN Drugs & Biologics Compendium 2023 National Comprehensive Cancer Network, Inc. Available at: <http://www.nccn.org>. Accessed July 9, 2024

VIII. APPROVALS

Signature on file at JHHC

DATE OF REVISION	SUMMARY OF CHANGE
07/17/2024	Policy creation

Review Date: 07/17/2024

Revision Date: